Technology transfer / Localization · Latin America · Announced 21 Oct 2026

Samsung Bioepis → Bahiafarma

Samsung Bioepis signed a 10-year Productive Development Partnership with Brazil's state lab Bahiafarma and Bionovis to supply its eculizumab biosimilar SB12 to the SUS from 2027, with manufacturing transferred to the partners over time.

Parties: Samsung Bioepis (South Korea) → Bahiafarma (Brazil)

Value
Undisclosed
Territory
Brazil — supply to the public health system (SUS) under a Productive Development Partnership
Therapeutic area
Rare / Orphan
Asset
SB12 (eculizumab)
Announced
21 Oct 2026

Our analysis

Why this matters

Samsung Bioepis announced on 21 October 2026 a 10-year agreement to supply SB12, its biosimilar of eculizumab (reference product Soliris), to Brazil's public health system (SUS) starting in 2027. The deal is structured as a Productive Development Partnership (PDP) with two Brazilian partners: Bahiafarma, a state-level public laboratory, and Bionovis, a local pharmaceutical company. Samsung Bioepis supplies finished product at first, and manufacturing responsibilities move gradually to the Brazilian partners. No contract value was disclosed.

The company cites IQVIA data showing Brazilian public spending on eculizumab exceeded BRL 947 million (about US$171 million) in 2025. ANVISA approved SB12 as a Soliris biosimilar in December 2024 for PNH and aHUS.

The full analysis is free to read with a work email on this page.

Source: Pharma Manufacturing

More deals involving Samsung Bioepis or Bahiafarma

Latest deals

All Latin America deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →